DarioHealth (DRIO) Competitors

DarioHealth logo
$1.13 -0.02 (-2.09%)
As of 03:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.

DRIO vs. CCLD, HIT, ONMD, AIFF, and ITOC

Should you buy DarioHealth stock or one of its competitors? DarioHealth's main competitors and comparable companies include CareCloud (CCLD), Health In Tech (HIT), OneMedNet (ONMD), Firefly Neuroscience (AIFF), and Itonic (ITOC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does DarioHealth compare to CareCloud?

DarioHealth (NASDAQ:DRIO) and CareCloud (NASDAQ:CCLD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

DarioHealth has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, CareCloud has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 10.2% of CareCloud shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by insiders. Comparatively, 14.8% of CareCloud shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

DarioHealth presently has a consensus target price of $7.75, indicating a potential upside of 573.91%. Given DarioHealth's higher probable upside, analysts plainly believe DarioHealth is more favorable than CareCloud.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DarioHealth
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
CareCloud
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, CareCloud had 1 more articles in the media than DarioHealth. MarketBeat recorded 13 mentions for CareCloud and 12 mentions for DarioHealth. CareCloud's average media sentiment score of 0.66 beat DarioHealth's score of 0.25 indicating that CareCloud is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DarioHealth
0 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
CareCloud
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

CareCloud has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than CareCloud, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DarioHealth$22.36M0.50-$41.71M-$3.90N/A
CareCloud$120.50M0.79$10.80M$0.1317.15

CareCloud has a net margin of 7.36% compared to DarioHealth's net margin of -159.85%. CareCloud's return on equity of 36.92% beat DarioHealth's return on equity.

Company Net Margins Return on Equity Return on Assets
DarioHealth-159.85% -55.10% -32.96%
CareCloud 7.36%36.92%16.40%

Summary

CareCloud beats DarioHealth on 12 of the 15 factors compared between the two stocks.

How does DarioHealth compare to Health In Tech?

DarioHealth (NASDAQ:DRIO) and Health In Tech (NASDAQ:HIT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

DarioHealth has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Health In Tech has a beta of 3.02, suggesting that its share price is 202% more volatile than the broader market.

In the previous week, DarioHealth had 1 more articles in the media than Health In Tech. MarketBeat recorded 12 mentions for DarioHealth and 11 mentions for Health In Tech. DarioHealth's average media sentiment score of 0.25 beat Health In Tech's score of 0.10 indicating that DarioHealth is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DarioHealth
0 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Health In Tech
0 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Health In Tech has higher revenue and earnings than DarioHealth. Health In Tech is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DarioHealth$22.36M0.50-$41.71M-$3.90N/A
Health In Tech$32.83M0.66-$12.45M-$0.19N/A

Health In Tech has a net margin of 0.00% compared to DarioHealth's net margin of -159.85%. Health In Tech's return on equity of 0.00% beat DarioHealth's return on equity.

Company Net Margins Return on Equity Return on Assets
DarioHealth-159.85% -55.10% -32.96%
Health In Tech N/A N/A N/A

DarioHealth currently has a consensus price target of $7.75, suggesting a potential upside of 573.91%. Health In Tech has a consensus price target of $3.50, suggesting a potential upside of 961.25%. Given Health In Tech's stronger consensus rating and higher possible upside, analysts clearly believe Health In Tech is more favorable than DarioHealth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DarioHealth
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Health In Tech
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

33.4% of DarioHealth shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by insiders. Comparatively, 71.0% of Health In Tech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Health In Tech beats DarioHealth on 12 of the 16 factors compared between the two stocks.

How does DarioHealth compare to OneMedNet?

DarioHealth (NASDAQ:DRIO) and OneMedNet (NASDAQ:ONMD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

OneMedNet has lower revenue, but higher earnings than DarioHealth. OneMedNet is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DarioHealth$22.36M0.50-$41.71M-$3.90N/A
OneMedNet$1.36M21.19-$2.80M-$1.60N/A

DarioHealth currently has a consensus price target of $7.75, suggesting a potential upside of 573.91%. Given DarioHealth's stronger consensus rating and higher possible upside, equities analysts clearly believe DarioHealth is more favorable than OneMedNet.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DarioHealth
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
OneMedNet
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, DarioHealth had 10 more articles in the media than OneMedNet. MarketBeat recorded 12 mentions for DarioHealth and 2 mentions for OneMedNet. OneMedNet's average media sentiment score of 0.65 beat DarioHealth's score of 0.25 indicating that OneMedNet is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DarioHealth
0 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
OneMedNet
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

DarioHealth has a net margin of -159.85% compared to OneMedNet's net margin of -584.20%. OneMedNet's return on equity of 0.00% beat DarioHealth's return on equity.

Company Net Margins Return on Equity Return on Assets
DarioHealth-159.85% -55.10% -32.96%
OneMedNet -584.20%N/A -521.20%

33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 1.0% of OneMedNet shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by insiders. Comparatively, 50.2% of OneMedNet shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

DarioHealth has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, OneMedNet has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market.

Summary

DarioHealth beats OneMedNet on 8 of the 15 factors compared between the two stocks.

How does DarioHealth compare to Firefly Neuroscience?

DarioHealth (NASDAQ:DRIO) and Firefly Neuroscience (NASDAQ:AIFF) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

In the previous week, DarioHealth had 10 more articles in the media than Firefly Neuroscience. MarketBeat recorded 12 mentions for DarioHealth and 2 mentions for Firefly Neuroscience. Firefly Neuroscience's average media sentiment score of 0.28 beat DarioHealth's score of 0.25 indicating that Firefly Neuroscience is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DarioHealth
0 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Firefly Neuroscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Firefly Neuroscience has lower revenue, but higher earnings than DarioHealth. Firefly Neuroscience is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DarioHealth$22.36M0.50-$41.71M-$3.90N/A
Firefly Neuroscience$1.14M12.38-$19.88M-$0.46N/A

33.4% of DarioHealth shares are held by institutional investors. Comparatively, 5.0% of Firefly Neuroscience shares are held by institutional investors. 3.5% of DarioHealth shares are held by company insiders. Comparatively, 6.9% of Firefly Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

DarioHealth has a net margin of -159.85% compared to Firefly Neuroscience's net margin of -386.15%. DarioHealth's return on equity of -55.10% beat Firefly Neuroscience's return on equity.

Company Net Margins Return on Equity Return on Assets
DarioHealth-159.85% -55.10% -32.96%
Firefly Neuroscience -386.15%-71.97%-59.30%

DarioHealth has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Firefly Neuroscience has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

DarioHealth presently has a consensus price target of $7.75, indicating a potential upside of 573.91%. Given DarioHealth's stronger consensus rating and higher probable upside, equities analysts clearly believe DarioHealth is more favorable than Firefly Neuroscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DarioHealth
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Firefly Neuroscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

DarioHealth beats Firefly Neuroscience on 10 of the 15 factors compared between the two stocks.

How does DarioHealth compare to Itonic?

Itonic (NASDAQ:ITOC) and DarioHealth (NASDAQ:DRIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

In the previous week, DarioHealth had 10 more articles in the media than Itonic. MarketBeat recorded 12 mentions for DarioHealth and 2 mentions for Itonic. Itonic's average media sentiment score of 1.39 beat DarioHealth's score of 0.25 indicating that Itonic is being referred to more favorably in the media.

Company Overall Sentiment
Itonic Positive
DarioHealth Neutral

DarioHealth has a consensus price target of $7.75, indicating a potential upside of 573.91%. Given DarioHealth's stronger consensus rating and higher possible upside, analysts clearly believe DarioHealth is more favorable than Itonic.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Itonic
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
DarioHealth
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

33.4% of DarioHealth shares are held by institutional investors. 3.5% of DarioHealth shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Itonic has a beta of 3.1, indicating that its share price is 210% more volatile than the broader market. Comparatively, DarioHealth has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

Itonic has a net margin of 0.00% compared to DarioHealth's net margin of -159.85%. Itonic's return on equity of 0.00% beat DarioHealth's return on equity.

Company Net Margins Return on Equity Return on Assets
ItonicN/A N/A N/A
DarioHealth -159.85%-55.10%-32.96%

Itonic has higher earnings, but lower revenue than DarioHealth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Itonic$520K26.54-$5.10MN/AN/A
DarioHealth$22.36M0.50-$41.71M-$3.90N/A

Summary

Itonic and DarioHealth tied by winning 7 of the 14 factors compared between the two stocks.

Get DarioHealth News Delivered to You Automatically

Sign up to receive the latest news and ratings for DRIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DRIO vs. The Competition

MetricDarioHealthHealthcare Technology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$11.04M$1.93B$7.73B$11.61B
Dividend YieldN/A3.89%2.46%4.43%
P/E Ratio-0.2941.7834.1629.83
Price / Sales0.495.668.475.65
Price / CashN/A15.8421.9322.50
Price / Book0.114.634.373.65
Net Income-$41.71M-$19.09M$3.52B$392.18M
7 Day Performance-52.89%-7.62%-5.48%-4.27%
1 Month Performance-76.64%-5.80%-4.62%-6.75%
1 Year Performance-91.94%-11.29%-1.57%-7.22%

DarioHealth Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DRIO
DarioHealth
3.1228 of 5 stars
$1.13
-2.1%
$7.75
+588.3%
-90.2%$11.04M$22.36MN/A165
CCLD
CareCloud
2.4337 of 5 stars
$1.80
+4.7%
N/A-28.8%$76.48M$120.50M25.713,650
HIT
Health In Tech
1.7296 of 5 stars
$0.61
+6.8%
$3.50
+471.0%
-79.4%$40.17M$32.83MN/A91
ONMD
OneMedNet
1.3976 of 5 stars
$4.54
+7.8%
N/A-65.3%$26.92M$1.36MN/A23
AIFF
Firefly Neuroscience
0.39 of 5 stars
$1.04
+6.1%
N/A-39.0%$16.32M$1.14MN/A17

Related Companies and Tools


This page (NASDAQ:DRIO) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners